Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, ...

The following is a summary of “Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the ...

SCY-247 inhibits glucan synthase, an enzyme involved in the formation of 1,3-beta-D-glucan, an essential component of the ...

An estimated 1.5 million deaths worldwide are attributed to invasive fungal diseases annually. 5 Of these, hospital-acquired infections—most frequently caused by species of Candida—account for ...

Vaginal infections, often termed "Infectious Vaginitis," are common concerns for women across the lifespan, with a higher ...

Caspofungin was approved for use in Costa Rica in October 2001 (Cancidas; Merck Sharp and Dohme) for patients older than 16 years, with invasive Candida spp. or Aspergillus spp. that fail to ...

a Comparison of adverse effects for all three echinocandins from their respective clinical trial for treatment of esophageal candidiasis where fluconazole was the comparator agent. Michele I.

Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS (SCYX – Research Report) yesterday and set a price target of ...

Expanded screening criteria helped a New York City hospital identify more patients who were colonized with the ...